Collaboration and Licensing

NapaJen Pharma is uniquely positioned to serve as a partner-of-choice for biotechnology and pharmaceutical companies focused on oligonucleotide therapeutics:

  1. Our novel immune cell-targeted oligonucleotide delivery platform provides broad opportunities for NapaJen Pharma to collaborate with companies seeking a cell-specific delivery technology to pair for development of oligonucleotide therapeutics. Learn more about collaboration opportunities. Collaboration Page
  2. Our lead clinical program, NJA-730, is a novel oligonucleotide drug that offers compelling licensing opportunities. The drug has potential therapeutic application for graft-versus-host disease (GVHD) and numerous other inflammatory immunoreactive indications. Learn more about licensing opportunities. Licensing Page